Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

MDL 19,205

Known as: MDL 19205, MDL-19,205, MDL-19205 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
SummaryThe cardiac and coronary vasodilator effects of MDL 17043 and MDL 19205 were compared in isolated, blood-perfused… Expand
  • figure 2
  • figure 3
  • figure 5
  • figure 7
  • figure 10
1987
1987
Summary Piroximone (MDL 19205), a new imidazole derivative with positive inotropic and vasodilating properties, was administered… Expand
1987
1987
MDL 19205 4-ethyl-1-,3-dihydro-5-(4-pyridinylcarbonyl)-2H-imidazol-2-one, a new cardioactive agent, has been shown to increase… Expand
1986
1986
Piroximone (MDL 19,205), a new phosphodiesterase inhibitor with positive inotropic and vasodilating properties, was administered… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
1986
1986
Summary: Piroximone (MDL 19,205), a new imidazolone derivative, was given intravenously to 14 patients with congestive heart… Expand
1984
1984
MDL 19205, 4-ethyl-l, 3-dihydro-5-(4-pyri-dinyl-carbonyl)-2 H-imidazol-2-one, is a new drug with cardiotonic properties. Its… Expand
1984
1984
The cardiovascular properties of a new cardiotonic agent, MDL 19205, were investigated in anesthetized and conscious dogs and in… Expand
1984
1984
The hemodynamic and neurohumoral effects of cummulative intravenous doses of piroximone (MDL 19205), a noncatecholamine… Expand
  • table 1
  • figure 3
  • figure 4
1984
1984
Various in vitro and in vivo techniques were used to evaluate the cardiovascular actions of MDL 19205, a new cardiotonic agent… Expand
1983
1983
A high-performance liquid chromatographic method has been developed for the analysis of plasma and urine concentrations of a new… Expand